Skip to main content

miR-103 Derived from Bone Marrow Mesenchymal Stem Cell (BMSC) Retards the Chemo-Resistance Through Targeted-Regulation of TP53 Regulated Inhibitor of Apoptosis 1 (TRIAP1) in Breast Cancer

Buy Article:

$110.00 + tax (Refund Policy)

The chemo-resistance was one of the major reasons for the treatment failure for breast cancer. Our study aimed to discuss the action of miR-103 derived from BMSC on retarding the chemo-resistance through targeted-regulating TRIAP1 in breast cancer. The cisplatin-resistant breast cancer cells were cultivated and transfected with si-RNA targeting miR-103 followed by analysis of cell invasion, migration and apoptosis by Transwell. MiR-103 target gene was analyzed with bioinformatics method and dual-luciferase reporter assay. TRIAP1 expression was measured by Western Blot. The cell apoptosis was reduced when miR-103 expression was restrained along with enhanced cell proliferation. The co-cultivation with BMSC in vitro could upregulate TRIAP1 expression in breast cancer cells. In cells transfected with si-miR-103, the expression of TRIAP1 was reduced, cell apoptosis was increased and invasion was decreased. In conclusion, the chemo-resistance is induced and the malignant invasion of breast cancer cells is retarded by co-cultivation with mikR-103 derived from BMSC which might be through regulating the expression of TRIAP.

Keywords: Breast Cancer; Cisplatin; Drug Resistance; miR-103

Document Type: Research Article

Affiliations: Department of Pathology, The General Hospital of Western Military Command, Chengdu, Sichuan, 610000, China

Publication date: June 1, 2022

More about this publication?
  • Journal of Biomaterials and Tissue Engineering (JBT) is an international peer-reviewed journal that covers all aspects of biomaterials, tissue engineering and regenerative medicine. The journal focuses on the broad spectrum of research topics including all types of biomaterials, their properties, bioimplants and medical devices, biofilms, bioimaging, BioMEMS/NEMS, biosensors, fibers, tissue scaffolds, tissue engineering and modeling, artificial organs, tissue interfaces, interactions between biomaterials, blood, cells, tissues, and organs, regenerative medicine and clinical performance.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content